Form 4: CytomX Therapeutics SVP, Chief Scientific Officer Marcia Belvin Reports Sale of Shares for Tax Obligations
SEC Form 4 Filing
Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, sold 12,795 shares of common stock on March 19, 2024, to cover tax obligations related to vesting restricted stock units.
Summary
- On March 19, 2024, Marcia Belvin, the SVP, Chief Scientific Officer of CytomX Therapeutics, sold 12,795 shares of common stock.
- The sale was executed at a price of $2.0855 per share.
- The transaction was conducted to satisfy tax or other government withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Belvin directly owns 168,579 shares of CytomX Therapeutics, Inc., which includes 109,166 restricted stock units.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no inherent positive or negative implications for the company's overall outlook.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The sale of shares by an officer may have a minor impact on shareholders due to the slight dilution of equity.
Key Dates
| Date | Description |
|---|---|
| 03/19/2024 | Date of stock sale transaction. |
| 03/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.